Mallinckrodt MNK shares are trading higher on Wednesday.
The company announced it received clearance from Health Canada to start on a pilot trial of high dose inhaled nitric oxide therapy for coronavirus infection and associated lung complications.
Mallinckrodt is a manufacturer of specialty pharmaceuticals, generic drugs and imaging agents.
Mallinckrodt's stock was trading up 16% to $2.30 per share in Wednesday’s pre-market session. The stock has a 52-week high of $23.90 and a 52-week low of $1.
Related Links:
Mallinckrodt Plummets On Report Of Possible Generics Business Bankruptcy
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
